$XBI $81.16 | -4.3%
Covid Updates
$NRXP -13.2% NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progress source
Pipeline Updates
$RVNC -3.0% Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines source
$MBRX -13.3% Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma source
$UBX +2.8% UNITY BIOTECHNOLOGY TO PRESENT CLINICAL DATA AT THE ASSOCIATION FOR RESEARCH IN VISION & OPHTHALMOLOGY (ARVO) 2022 ANNUAL MEETING source
$SRRK +0.3% Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress source
Business Updates
$CDXS -0.3% Codexis and seqWell Announce Strategic Investment and Partnership Initiation source
Posted by FS/JM